SPERO THERAPEUTICS INC (NASDAQ: SPRO)

1. Introduction

SPERO THERAPEUTICS INC is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2013 and publicly listed since November 2, 2017, SPRO is focused on developing treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.

Trading data (2025-05-28)

• Price: $2.0898
• Change: +206.42%
• Volume: 36,791,009 shares
• Exchange: NASDAQ Global Market

2. Corporate Structure

• Headquarters: Cambridge, MA
• Employees: 11–50 (LinkedIn)
• Auditor: PricewaterhouseCoopers
• Transfer agent: Computershare
• No dividend or Dividend Reinvestment Plan (DRIP) offered
• Environmental, Social, and Governance (ESG) program under development

Management experience

• Combined leadership tenure: over 175 years in biotechnology and pharmaceutical sectors
• Track record: 11 approved antibacterial products
• Board chaired by Frank Thomas; Interim President & CEO: Esther Rajavelu

3. Recent Developments and News

• 2025-01-10: Board appoints Esther Rajavelu as Interim President & CEO and Frank Thomas as Chair. This change follows a Wells Notice from the SEC related to 2022 disclosures.
• 2024-12-31: Phase 3 PIVOT-PO trial of oral tebipenem HBr exceeds 60% enrollment; full enrollment is expected in the second half of 2025.
• 2025-05-02: Esther Rajavelu confirmed as President & CEO and nominated to the Board.
• May 2025: The company reported via LinkedIn that the PIVOT-PO trial met its primary endpoint and will conclude early.
• Program update: Development of SPR720 has been suspended; data analysis and next-step determinations are underway.

4. Financial and Strategic Analysis

Metric	Value
Market Cap	$38.13 million
Enterprise Value	–$6.80 million
Price/Sales (ttm)	1.31
Price/Book (mrq)	1.13
Profit Margin (ttm)	–156.48%
Return on Assets (ttm)	–37.21%
Return on Equity (ttm)	–107.28%
Revenue (ttm)	$44.58 million
Net Loss (ttm)	–$69.76 million
Cash & Cash Equivalents	$52.9 million (12/31)
Cash Runway	Into mid-2026

Strategic partnerships and funding

• Global license agreement with GSK for tebipenem HBr
• Funding from BARDA, DoD, and NIH for SPR206 and tebipenem studies
• Focus on development of oral first-in-class carbapenem for complicated urinary tract infections

5. Market Position and Industry Context

• Specialty niche: oral therapies for serious bacterial infections and rare diseases
• Potential to replace hospital-based intravenous (IV) regimens for complicated urinary tract infections (cUTI) and acute pyelonephritis
• Low beta (0.23) reflects reduced volatility compared to broader markets
• Small-cap profile presents clinical-stage risks; success is dependent on trial outcomes and regulatory approvals
• Competes with established IV antibiotic developers and emerging biotechnology firms focused on MDR

tl;dr

On May 28, 2025, SPRO shares increased by 206.42% to $2.0898 with a trading volume of 36.8 million shares. In May 2025, the company reported that its Phase 3 PIVOT-PO trial of oral tebipenem HBr met its primary endpoint and will conclude early, with full enrollment expected in the second half of 2025. Esther Rajavelu has served as President & CEO since May 2, 2025. The company's cash and funding commitments support operations into mid-2026, facilitating the tebipenem HBr pivotal trial and the readiness of SPR206 for Phase 2.